--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About IBRX20260220C4.5
Pharmaceutical
ImmunityBio, Inc., was incorporated on October 7, 2002 under the name of ZelleRx Corporation, Illinois, and on January 22, 2010, the company changed its name to Conkwest Co., Ltd. ImmunityBio is a leading late-stage immunotherapy company that activates the innate and adaptive immune systems to treat serious unmet needs in oncology and infectious diseases. The company is a leading manufacturer of ready-made natural killer cell therapies in clinical formulations, a comprehensive platform for memory NK cells, along with antibody cytokine fusion proteins, albumin-binding chemical immunomodulators and vaccine vectors. By combining these NK, macrophage and T-cell activation platforms, the company believes that ImmunityBio is a leader in immunotherapy with late-stage clinical development across multiple tumor types and infectious diseases.
